CGIX 5.76 Cancer Genetics Inc $CGIX Hit a 52 week low of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 20, 2014 at 11:14 AM

CGIX 5.76 Cancer Genetics Inc $CGIX Hit a 52 week low of 5.56 Closing the day 10:45 at 5.76 -0.19 -3.19% With a day low of 5.56 and a total volume of 41,986.

CGIX Recent Posts: http://investorshangout.com/Cancer-Genetics-Inc-CGIX-88009/

CGIX Cancer Genetics Inc Recent Headline News

Cancer Genetics, Inc. to Present at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire - Mon Nov 17, 6:50AM CST
-- Cancer Genetics will present two posters on diffuse large B-cell lymphoma (DLBCL), the most common form of B-cell cancers.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. Recognized in Deloitte's 2014 Technology Fast 500(TM) Awards
GlobeNewswire - Fri Nov 14, 7:06AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the company"

, an emerging leader in DNA-based cancer diagnostics, today announced it ranked 303 on Deloitte's Technology Fast 500(TM), a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. CGI grew 296% percent as measured by revenues during this period.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc to Present at Canaccord Genuity Medical Technology & Diagnostics Conference
GlobeNewswire - Thu Nov 13, 6:55AM CST
Cancer Genetics, Inc., (Nasdaq:CGIX) an emerging leader in DNA-based cancer diagnostics, announced today that the company's CEO, Panna Sharma, will present at the upcoming Canaccord Genuity Medical Technology & Diagnostics Conference. The event, which will be held at the Westin Grand Central in New York on Thursday, November 20, will profile over 80 public and private med-tech and diagnostic companies.
CGIX: 5.73 (-0.22)

Cancer Genetics wins second patent for FHACT test to improve cervical cancer detection for up to 2m women in the US each year
M2 - Wed Nov 12, 7:02AM CST
Cancer diagnostics company Cancer Genetics (NasdaqCM:CGIX) disclosed on Tuesday the receipt of the second US patent (US Patent No. 8,883,414) for its proprietary FISH-based HPV-Associated Cancer Test (FHACT) for cervical cancer detection in patients.
CGIX: 5.73 (-0.22)

RedChip Issues Research Note on Cancer Genetics
GlobeNewswire - Wed Nov 12, 7:00AM CST
RedChip Companies, Inc., today announced it has issued a research note on Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics that personalizes the clinical management of difficult-to-diagnose cancers.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc to Present on Company's Targeted Next-Generation Sequencing Panels at AMP
GlobeNewswire - Wed Nov 12, 6:55AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that it will present on its next generation sequencing (NGS) panels for hematological malignancies at the Association for Molecular Pathology's (AMP) 2014 Annual Meeting in Harbor, MD. Principal clinical scientist Charles Ma, Ph.D., will present "Developing NGS-based Clinical Assays for Hematological Neoplasms at CGI" on Wednesday, November 12 at 3 p.m. EST. The talk, which is sponsored by Illumina, will cover the development and clinical utility of the company'sNGS panels for hematologic malignancies, specifically for CLL (chronic lymphocytic leukemia) and Myeloid disorders.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc Receives Second Patent for Genomic Cervical Cancer Test; Strengthens Position of FHACT(R)
GlobeNewswire - Tue Nov 11, 6:55AM CST
-- Company receives second patent (US Patent No. 8,883,414) for FHACT(R)
CGIX: 5.73 (-0.22)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST

UCP: 11.32 (-0.01), JRJC: 6.87 (+0.13), NAVB: 1.21 (-0.01), SANW: 3.68 (+0.16), PLPM: 1.60 (+0.02), RYN: 26.89 (+0.48), INFU: 2.87 (+0.02), LIOX: 5.08 (+0.12), DY: 25.97 (+0.30), MTZ: 24.55 (+0.45), CGIX: 5.73 (-0.22), MUX: 1.51 (+0.05), OREX: 5.67 (-0.01), URRE: 2.14 (unch), ACHN: 13.12 (+0.21), REN: 2.62 (+0.13), MPO: 2.82 (+0.17), AKBA: 14.50 (-0.74), TRX: 1.15 (+0.08), PLNR: 7.27 (+0.04)

Cancer Genetics' (CGIX) CEO Panna Sharma on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 11:28AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics ups revenues 88% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:03AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics Announces Strong Third Quarter With Growth Across All Categories
GlobeNewswire - Mon Nov 10, 7:43AM CST
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today financial and operating results for the third quarter ended September 30, 2014.
CGIX: 5.73 (-0.22)

Cancer Genetics beats by $0.07, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:58AM CST

CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. to Report Third Quarter 2014 Financial Results on Monday, November 10
GlobeNewswire - Thu Oct 30, 7:30AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014. The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. Granted Patent for Genomic Probe Set Used in Proprietary Test for Cervical and Other HPV-Associated Cancers
GlobeNewswire - Tue Oct 21, 6:59AM CDT
> Issuance of patent 8,865,882 covers four probe set used in CGI's proprietary FISH-based HPV-Associated Cancer Test (FHACT(R))
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML
GlobeNewswire - Mon Oct 13, 6:45AM CDT
> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
CGIX: 5.73 (-0.22)

Global Genetic Testing Market - Industry Analysis And Market Forecast 2014-2020
PR Newswire - Thu Oct 09, 2:50PM CDT
Genetic testing is the analysis of genes, chromosomes, or proteins to help predict the risk of disease, identify carriers (individuals who do not have the disease but have a copy of the disease gene) of disease, diagnose disease, or determine the likely course of a disease. Cytogenetics, Molecular Genetics, Cancer Genetics, Prenatal Screening and Prenatal diagnosis are type of genetic tests that involves examining a person's genetic material taken from cells in a sample of blood or, occasionally, from other body fluids or tissues.
CGIX: 5.73 (-0.22)

Cancer Genetics Inc. to Provide Updates About the Company's Portfolio of Targeted Molecular Diagnostics at Analyst Day on September 25, 2014
GlobeNewswire - Wed Sep 24, 6:45AM CDT
Cancer Genetics Inc. (Nasdaq:CGIX) ("CGI" or "the Company"

, an emerging leader in DNA-based cancer diagnostics, today released an agenda for its upcoming Analyst Day, to be held Thursday, September 25 in Raleigh, North Carolina.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. and Beth Israel Deaconess Medical Center Enter Into Collaboration to Correlate Genomic Profiles to Patient Outcome in Diffuse Large B-Cell Lymphoma
GlobeNewswire - Tue Sep 23, 6:45AM CDT
-- Study will correlate genetic markers to outcome in ~200 patients with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
CGIX: 5.73 (-0.22)

Cancer Genetics, Inc. to Present at Aegis Healthcare and Technology Conference on Thursday, September 11, 2014
GlobeNewswire - Wed Sep 10, 6:59AM CDT
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that Panna Sharma will present at the Aegis Healthcare and Technology Conference on Thursday, September 11, 2014 at 8:30 am Pacific Daylight Time (11:30 am EDT).
CGIX: 5.73 (-0.22)

Cancer Genetics' Proprietary IVD for Cervical Cancer, FHACT(R), Receives CE
GlobeNewswire - Tue Sep 02, 7:15AM CDT
- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"

, an emerging leader in DNA-based cancer diagnostics, announced today that their proprietary DNA-probe based test for cervical cancer (FHACT(R)) has received the CE Marking.
CGIX: 5.73 (-0.22)

Vyant Bio, Inc. (VYNT) Stock Research Links

VYNT Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nurminen Logistics Doubles Sweden–Italy Rail Capacity

Nurminen Logistics Betting Big on Rail Expansion Feeling the pulse of the logistics world is much like trying to catch lightning in a bottle, but Nurminen Logistics seems to have found its rhythm. They're ramping up their services between Sweden and Italy, leveraging rail to push the envelope. Come October, they're doubling down from one to two weekly departures, giving...

Dr. Liedtka's LIVE Model: Balance Life’s Priorities

Finding Balance in a Chaotic World Forget the market roller coaster for a second. Let's chat about something else that often feels like a roller coaster—life itself. Dr. Karl D. Liedtka's book, "Be Present, LIVE Fully," dives into that hot mess and offers a way to get a grip on your own sanity. This isn't just another self-help book filled with empty platitudes; it's...

Hoymiles' V2X Charger Revamps Home Energy Control

Revolutionizing Home Energy with Hoymiles Here's a twist in the world of home energy that'll make any enthusiast pause—Hoymiles has launched their V2X DC Charger. This little number isn’t just a step up; it’s a giant leap toward integrating electric vehicles (EVs) into your home's energy system like never before. Nestled in Hangzhou, they've rolled this out as a...

AXIS-Y: Global Expansion Fueled by KRW 430B Valuation

Rewriting the Playbook in Global Skincare AXIS-Y decided to do things their way, not just because they could afford to, but because they believed in their vision. Their strategy defies the trends-driven tactics of this cutthroat beauty world. Instead, they’ve been all about climate-inspired products and vegan, cruelty-free standards. And now, after notching up some...

Potensic's ATOM 3 Invites Drone Creators to 'See Beyond'

Innovative Features of Potensic's New Drone Potensic decided to shake things up a bit this year at IFA Berlin, showcasing their new creation: the ATOM 3 drone. Under the theme "SEE BEYOND," Potensic’s message to creators was clear—there’s more to explore in the world of visual storytelling than meets the eye. This drone isn't just another gadget; it's an invitation...

FOTON Accelerates Global Push with European Focus

The Road to Global Dominance Ever feel like someone’s racing past you while others try to catch up? That’s FOTON in the relentless world of commercial vehicles. This juggernaut of a company isn't just satisfied with leading the pack; they’ve got their eyes set on redefines the game, especially with their new moves in Europe. A Shift in Strategy Right now, the...

Supernova SPAC Lawsuit: Settlement Proposed, $3M on Table

Legal Clouds Over Supernova's SPAC Adventure Alright, folks, buckle up, because whenever you mix SPACs and lawsuits, you're in for a roller coaster. Supernova Partners Acquisition Company, Inc. stands right at the heart of a class action lawsuit, and it's been cooking ever since the court in Delaware gave it a nudge forward. Settlement Talk: What's on the Table? So here's...

AION UT Sets New Safety Standard in Euro NCAP 2026

The New Gold Standard in Safety for Small EVs Hop into your favorite auto forum and you'll hear more than a buzz—it's a full-blown ruckus. The reason? GAC’s AION UT just nabbed a 2026 Euro NCAP Five-Star Safety Rating. Now, this isn’t just another accolade in a crowded trophy room; it’s a statement, a seismic shift in how small electric vehicles stack up in terms...

Interventional Ophthalmology: Early Eye Care Strategies Evolve

Proactive Eye Care: The New Frontier Today's eye care landscape is all about catching things early, folks. Long gone are the days of waiting for eyesight to deteriorate before rushing to the nearest eye doc. In Racine, interventional ophthalmology is shifting gears towards preventive care—looking ahead to stop eye diseases in their tracks before they muck up a person's...

AB SKF to Hold EGM, Spin Off Automotive Assets

SKF's Extraordinary Meeting: A Pivotal Moment AB SKF, a heavyweight in the industrial technology sector, is summoning its shareholders for an Extraordinary General Meeting on October 1, 2026. The venue? The Elite Park Avenue Hotel in Gothenburg, Sweden—sounds fancy, but don't expect to hear a string quartet at this shindig. What's truly on the agenda is a critical...